Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 4/20 | 0.70 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.70 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.70 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.67 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.67 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.65 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.63 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.63 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.63 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.63 |
| ▸ | PARG | Q86W56 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20419143 | 1.00 | P2RX1 (0.70) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL29476737 | 1.00 | P2RX1 (0.70) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL19493160 | 1.00 | P2RX1 (0.70) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL29476738 | 1.00 | P2RX1 (0.70) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL3163036 | 1.00 | P2RX1 (0.70) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL23982340 | 1.00 | P2RX1 (0.70) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL12932304 | 1.00 | P2RX1 (0.70) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL250251 | 1.00 | P2RX1 (0.70) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL23856115 | 0.99 | P2RX1 (0.69) | P2RX1P2RX3P2RX2P2RY1P2RX4 | |
| SCHEMBL22498804 | 0.99 | P2RX1 (0.68) | P2RX1P2RX3P2RX2P2RY1P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060057583-A1 | Novel compositions and methods for controlling the extendability of various components used in copying or amplification steps | ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC. | 2006-03-16 | — | — | US | claimed |
| US-20260115182-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDRENS MEDICAL CENTER (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250163096-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana plc (GB) | 2025-05-22 | — | — | US | disclosed |
| US-20250032440-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | NATIONAL INSTITUTES OF HEALTH | 2025-01-30 | — | — | US | disclosed |
| US-12171755-B2 | PAPD5 inhibitors and methods of use thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240376143-A1 | SELECTION INHIBITION OF DNA POLYMERASE BETA BY A COVALENT INHIBITOR | THE JOHNS HOPKINS UNIVERSITY | 2024-11-14 | — | — | US | disclosed |
| US-12054510-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | NuCana plc (GB) | 2024-08-06 | — | — | US | disclosed |
| CN-115554309-B | Pharmaceutical composition and application thereof in preparation of products for preventing and treating mental diseases and/or sub-health mental states | 南京工业大学 | 2023-09-08 | — | — | CN | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| WO-1993011227-A1 | RECOMBINANT POLY(A) POLYMERASE | UNITED STATES BIOCHEMICAL CORPORATION (US) | 1993-06-10 | — | — | WO | disclosed |
| US-5102802-A | Phage RNA polmerases for transcribing plamsids produced by culturing; large scale, easily purified | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 1992-04-07 | — | — | US | disclosed |
| EP-0426756-A4 | RNA AND DNA AMPLIFICATION TECHNIQUES | — | 1991-11-21 | — | — | EP | disclosed |
| US-5037745-A | Genetic engineering | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 1991-08-06 | — | — | US | disclosed |
| EP-0439330-A2 | Amplification methods | ZENECA LIMITED (GB) | 1991-07-31 | — | — | EP | disclosed |
| EP-0426756-A1 | RNA AND DNA AMPLIFICATION TECHNIQUES | GENELABS TECHNOLOGIES, INC. (US) | 1991-05-15 | — | — | EP | disclosed |
| EP-0356021-A2 | A method for the amplification of nucleotide sequences | ZENECA LIMITED (GB) | 1990-02-28 | — | — | EP | disclosed |
| WO-1990001065-A1 | RNA AND DNA AMPLIFICATION TECHNIQUES | GENELABS INCORPORATED (US) | 1990-02-08 | — | — | WO | disclosed |
| WO-1990001064-A1 | SEQUENCE-SPECIFIC AMPLIFICATION TECHNIQUES | GENELABS INCORPORATED (US) | 1990-02-08 | — | — | WO | disclosed |
| US-4555486-A | USING POLYMERASE TO EXTEND STRANDS | CETUS CORPORATION (US) | 1985-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032440-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | NLN, PSEN2, PSEN1 | P2RX1 288/4885P2RX3 208/4885P2RX2 265/4885 |
| US-20240376143-A1 | SELECTION INHIBITION OF DNA POLYMERASE BETA BY A COVALENT INHIBITOR | POLB, POLA1, POLH | P2RX1 4506/4885P2RX3 4646/4885P2RX2 4581/4885 |
| US-12171755-B2 | PAPD5 inhibitors and methods of use thereof | PARP15, PAPSS1, PGA5 | P2RX1 4443/4885P2RX3 4265/4885P2RX2 4301/4885 |
| US-20260115182-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, TERT, BRCA1 | P2RX1 3152/4885P2RX3 3836/4885P2RX2 3891/4885 |
| US-12054510-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds | MTAP, ADA, ADORA2A | P2RX1 1384/4885P2RX3 1153/4885P2RX2 1293/4885 |
| US-20250163096-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, ADORA2A | P2RX1 1355/4885P2RX3 1110/4885P2RX2 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.